Assessing the burden of Taenia solium cysticercosis and echinococcosis.

This collection of articles provides an account of the papers delivered at the 19th International Conference of the World Association for the Advancement of Veterinary Parasitology (WAAVP)(held in New Orleans, LA, USA, from 10 to 14 August 2003) in a symposium session on assessing the burden of Taenia solium cysticercosis and echinococcosis organised and chaired by A. Lee Willingham III from the WHO/FAO Collaborating Center for Research and Training on Emerging and other Parasitic Zoonoses in Denmark and Peter M. Schantz from the Parasitic Diseases Division of the US Centers for Disease Control and Prevention, USA. The focus was on the persistence of the zoonotic parasitic diseases cysticercosis, caused by the pork tapeworm T. solium, and echinococcosis,caused by species of the tapeworm Echinococcus, and why these diseases are given very little attention on the national and international agendas in spite of the availability of tools to detect, treat,control and prevent them when it is quite clear in most instances that they are clearly associated with and help perpetuate poverty. A major reason for this is that in many endemic areas the presence and impact of these diseases are not known due to the lack of investigation and information thus policymakers are not aware of their burden and benefits of their control. Documentation is also needed to help increase awareness of the international community and hopefully result in financial and technical support being made available. Thus, burden assessments of cysticercosis and echinococcosis provide an essential evidence base for securing political will and financial and technical support as well as providing a basis for cost-benefit analysis of prevention and control efforts. In order to make an appropriate and full burden assessment one must consider the health, agricultural, social and other impacts of these parasitic zoonoses comprehensively. During the symposium presentations were given concerning current ongoing initiatives to assess the burden of cysticercosis and echinococcosis and examples of the impact of these diseases in both developing and developed countries were provided. In addition, cost factors related to vaccines for these cestode diseases were discussed and the possibilities for technical and financial support from multilateral agencies for assessments and interventions presented.

Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep.

Experimental vaccine trials against hydatid disease have been undertaken in sheep using the EG95 recombinant vaccine. Challenge infection was with viable Echinococcus granulosus eggs obtained from a New Zealand isolate (dog/sheep cycle), an Australian isolate (dingo/wallaby cycle) and an Argentine isolate (dog/sheep cycle). Vaccination with EG95 conferred a high degree of protection against challenge with all three parasite isolates (protection range 96-100%). Taken together, the trials demonstrated that 86% of vaccinated sheep were completely free of viable hydatid cysts when examined approximately 1 year after challenge infection. Vaccination reduced the number of viable cysts by 99.3% compared with unvaccinated controls. These results suggest that the EG95 vaccine could have wide applicability as a new tool for use in hydatid control campaigns.

Serum antibodies in canine echinococcosis.

Specific IgG, IgA and IgE antibodies against E. granulosus protoscolex antigen were detected by enzyme-linked immunosorbent assay (ELISA) in sera from dogs experimentally or naturally infected with E. granulosus. The specificities of the IgG, IgA and IgE ELISAs were 100, 100 and 97.3%, respectively. Sera from 626 dogs of different categories and geographic regions in Australia, Uruguay and Kenya were tested. There were distinct differences in antibody responses in experimentally infected canids and in the number of naturally infected dogs found seropositive, depending on geographic region. The overall sensitivities of the ELISA (IgG, IgA and IgE) ranged between 73 and 84%, except for one geographic region where it was 54%. Genetic differences of the dogs and/or antigenic variations of the parasite appear to be responsible for the variations in specific antibody levels in infected dogs. In average, approximately one third of dogs from hyperendemic hydatid regions, without E. granulosus worms at autopsy or negative for E. granulosus infection by arecoline testing, were seropositive for anti-E. granulosus antibodies, suggesting previous infection with or exposure to the parasite. The results of this study demonstrate that, although the diagnosis of current intestinal E. granulosus infection on an individual dog basis is not always reliable by serology, serum antibody ELISA is useful as an epidemiological/educational tool for seroprevalence studies on canine echinococcosis.